Evolving CNS Drug Discovery: Innovations and Challenges

Priya Mehta
Department of Pharmacological Research, AIIMS, New Delhi, India

*Corresponding Authors**

Priya Mehta
Department of Pharmacological Research, AIIMS, New Delhi, India
E-mail: priya.mehta@aiims.ac.in

Received: 01-Jul-2025; **Accepted:** 08-Aug-2025; **Published:** 08-Aug-2025

Introduction

Gene therapy, specifically utilizing Adeno-Associated Virus (AAV) vectors, presents immense promise for treating central nervous system disorders. Significant advancements in AAV vector design, delivery methods, and their application in preclinical and clinical settings for conditions such as Parkinson's, Alzheimer's, and various rare genetic neurological diseases are a current focus. Researchers are working to improve vector efficiency and specificity while addressing critical challenges related to immunogenicity and achieving widespread CNS distribution [1].

Neuroinflammation has become increasingly recognized as a critical driver in a range of CNS pathologies, including major neurodegenerative diseases, stroke, and various psychiatric disorders. This recognition has spurred exploration into novel therapeutic strategies. These strategies often target specific inflammatory pathways within the brain, focusing on modulating microglia activation, aiming for specific inflammatory mediators, and employing broader immunomodulatory approaches to develop more effective CNS drugs [2].

Delivering therapeutic agents effectively to the central nervous system remains a significant hurdle, primarily due to the formidable presence of the blood-brain barrier (BBB). Overcoming this barrier is essential for improving CNS drug efficacy. Recent detailed reviews highlight advanced strategies to achieve this, including the chemical modification of drugs, receptor-mediated transcytosis, the localized application of focused ultrasound, and the innovative use of nanoparticle-based delivery systems [3].

Artificial Intelligence (AI) and machine learning technologies are actively revolutionizing the field of CNS drug discovery. These powerful computational tools significantly accelerate crucial steps such as target identification, optimize the hit-to-lead process, and enhance the prediction of drug-like properties. Their application involves analyzing complex biological data, designing novel compounds, and ultimately strengthening preclinical studies, thereby expediting the development of new treatments for a variety of neurological and psychiatric disorders [4].

Oligonucleotide therapeutics, a class encompassing antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), represent a rapidly advancing area in drug development for neurological diseases. Progress in these precision medicines involves understanding their intricate mechanisms of action and confronting challenges related to their effective delivery and potential off-target effects. Their appeal lies in their potential to target previously considered 'undruggable' targets within the CNS [5].

Drug repurposing, a strategic approach focused on finding new therapeutic uses for existing drugs, offers an accelerated pathway for developing CNS treatments. This strategy benefits from leveraging compounds with already established safety profiles. Updated reviews cover recent successes and methodologies, detailing computational approaches, phenotypic screening, and clinical trials that underscore the promise of this cost-effective strategy across a spectrum of neurological and psychiatric conditions [6].

The inherent complexity of the CNS demands increasingly sophisticated models for effective drug discovery. Researchers are evaluating advanced in vitro models, such as human Induced Pluripotent Stem Cell (iPSC)-derived neurons and intricate organoids. These are complemented by refined in vivo models, including genetically engineered animal models, all emphasizing their utility in better recapitulating human disease pathology and significantly improving the translatability of preclinical findings to clinical outcomes [7].

Clinical trials specifically for neurodegenerative diseases encounter distinct challenges. These often include heterogeneous patient populations, the characteristically long progression of these diseases, and persistent difficulties in identifying appropriate biomarkers and clear endpoints. Innovative trial designs, adaptive methodologies, and advanced strategies for patient stratification are actively being discussed and implemented to enhance the efficiency and overall success rates of clinical development programs for CNS disorders [8].

Non-coding RNAs (ncRNAs), a diverse group including microRNAs and long non-coding RNAs, are understood to play crucial roles in both normal CNS function and pathological states. This understanding has opened up an emerging field of ncRNA-based therapeutics for neurological and psychiatric disorders. The discussion centers on their mechanisms as potential drug targets or direct therapeutic agents, alongside the challenges in developing stable, specific, and effectively deliverable ncRNA therapies [9].

Human brain organoids, which are three-dimensional cellular models meticulously derived from pluripotent stem cells, are revolutionizing CNS drug development. These models provide more physiologically relevant platforms compared to traditional two-dimensional cultures. Their utility is highlighted in modeling complex brain diseases, streamlining drug screening processes, and advancing personalized medicine, all while their current limitations are actively being addressed to accelerate the discovery of new

Cite this article: Mehta P,(2025) Evolving CNS Drug Discovery: *Innovations and Challenges. ncoa* 10: 238. DOI: 10.4172/2469-9780.2025.10.3.238

therapies [10].

Description

The therapeutic landscape for Central Nervous System (CNS) disorders is undergoing a significant transformation with the emergence of novel treatment modalities. Gene therapy, particularly employing Adeno-Associated Virus (AAV) vectors, demonstrates considerable potential for conditions like Parkinson's and Alzheimer's, focusing on enhanced vector efficiency and targeted delivery [1]. Alongside this, oligonucleotide therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are rapidly advancing as precision medicines capable of targeting previously 'undruggable' pathways in the CNS [5]. An emerging area involves non-coding RNAs (ncRNAs), such as microRNAs and long non-coding RNAs, which are pivotal in CNS function and pathology. Research now explores their potential as both drug targets and therapeutic agents, despite challenges in stability and specific delivery [9].

Addressing fundamental physiological barriers and pathological processes remains paramount. Neuroinflammation is increasingly recognized as a crucial factor in various CNS pathologies, encompassing neurodegenerative diseases, stroke, and psychiatric disorders. This understanding has led to the development of novel therapeutic strategies aimed at modulating microglia activation and targeting specific inflammatory mediators to create more effective CNS drugs [2]. Furthermore, the formidable blood-brain barrier (BBB) continues to pose a major hurdle for delivering therapeutic agents to the CNS. Advanced strategies are being developed to overcome this, including chemical modification of drugs, receptor-mediated transcytosis, focused ultrasound, and sophisticated nanoparticle-based delivery systems, all promising improved CNS drug efficacy [3].

Technological advancements are profoundly accelerating the drug discovery pipeline. Artificial Intelligence (AI) and machine learning are revolutionizing CNS drug discovery by speeding up target identification, optimizing hit-to-lead processes, and accurately predicting drug-like properties. These computational tools are vital for analyzing complex biological data and designing novel compounds, thereby enhancing preclinical studies for neurological and psychiatric disorders [4]. Complementing this, drug repurposing offers an accelerated and cost-effective route for developing new CNS treatments. By leveraging existing drugs with known safety profiles, this strategy capitalizes on computational approaches, phenotypic screening, and ongoing clinical trials to bring therapies to patients faster [6].

Refinements in both preclinical modeling and clinical trial methodologies are crucial for successful CNS drug development. The complexity of the CNS demands sophisticated models to accurately recapitulate human disease pathology and improve the translatability of preclinical findings. This includes advanced in vitro models like human Induced Pluripotent Stem Cell (iPSC)-derived neurons and brain organoids, alongside refined in vivo models such as genetically engineered animal models [7, 10]. These brain organoids, in particular, provide more physiologically relevant platforms for disease modeling, drug screening, and personalized medicine [10]. Despite these advances, clinical trials for neurodegenerative diseases still face significant challenges, including patient heterogeneity, lengthy disease progression, and difficulties in identifying appropriate biomarkers. Therefore, innovative trial designs, adaptive methodologies, and strategies for patient stratification are actively being implemented to improve the efficiency and success rates of these complex clinical development programs [8].

Conclusion

The field of Central Nervous System (CNS) drug discovery and therapy is rapidly evolving, driven by significant innovations. Gene therapy, particularly using Adeno-Associated Virus (AAV) vectors, shows substantial promise for neurological conditions like Parkinson's and Alzheimer's, with ongoing efforts to improve vector efficiency and delivery while managing immunogenicity. Neuroinflammation is increasingly understood as a core pathology in many CNS disorders, prompting the development of new therapeutic strategies that target inflammatory pathways and modulate microglia activation. A major persistent hurdle remains the blood-brain barrier (BBB), which restricts drug delivery. Advanced methods are being explored to overcome this, including chemical modifications, receptor-mediated transcytosis, focused ultrasound, and nanoparticle systems. Concurrently, Artificial Intelligence (AI) and machine learning are transforming early drug discovery by accelerating target identification, optimizing lead compounds, and enhancing preclinical prediction for new treatments. Precision medicine approaches are gaining traction, with oligonucleotide therapeutics like antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) showing potential for targeting previously undruggable CNS targets. Similarly, non-coding RNAs (ncRNAs) are emerging as both drug targets and therapeutic agents for neurological and psychiatric disorders, though challenges in stability and specific delivery persist. The strategy of drug repurposing offers a cost-effective and accelerated path to CNS treatments, leveraging existing compounds with known safety profiles, supported by computational approaches and phenotypic screening. Effective drug discovery also relies on sophisticated models; human Induced Pluripotent Stem Cell (iPSC)-derived neurons, brain organoids, and genetically engineered animal models are crucial for better recapitulating human disease pathology. Finally, clinical development for neurodegenerative diseases faces unique challenges, including patient heterogeneity and biomarker identification. Innovative trial designs and adaptive methodologies are being implemented to improve the efficiency and success rates of these complex programs.

References

1. Yan Y, Li X, Wu Z. Advances in AAV-mediated gene therapy for central nervous system disorders. *Mol Ther Methods Clin Dev.* 2023;30:288-301.

2. Tanga MLT, Monti S, Stohr EB. Targeting neuroinflammation in CNS drug discovery: *Novel therapeutic strategies. Biochem Pharmacol.* 2022;203:115161.

3. Zhang Z, Li Y, Chen Y. Strategies to overcome the blood-brain barrier for the delivery of therapeutic agents to the central nervous system. *Adv Drug Deliv Rev.* 2021;176:113898.

4. Brandon NJ, Maroun MF, *Low CH. Artificial intelligence and machine learning in CNS drug discovery and development. Drug Discov Today.* 2022;27:252-257.

5. Bennett CF, Lee RSF, Chang HS. Oligonucleotide therapeutics in neurological diseases: *Progress and challenges. Trends Neurosci.* 2020;43:16-29.

Cite this article: Mehta P,(2025) Evolving CNS Drug Discovery: *Innovations and Challenges. ncoa* 10: 238. DOI: 10.4172/2469-9780.2025.10.3.238

6. Salgado LA, Garcia MT, Sanchez JC. Drug repurposing for central nervous system disorders: *An updated review. Eur J Pharm Sci.* 2023;188:106423.

7. Smith PG, Jones CM, *Miller RE. Advanced in vitro and in vivo models for central nervous system drug discovery. J Neurochem.* 2021;158:1461-1479.

8. Miller ME, Jones SHK, *Smith RCA. Challenges and strategies in clinical trials for neurodegenerative diseases. Nat Rev Neurol.* 2020;16:529-543.

9. Jones ES, Davis RL, Green PT. Non-coding *RNA therapeutics for central nervous system disorders. Trends Pharmacol Sci.* 2024;45:105-116.

10. Lee YK, Park JM, *Kim SM. Human brain organoids for CNS drug development and disease modeling. J Control Release.* 2023;361:216-231.

Cite this article: Mehta P,(2025) Evolving CNS Drug Discovery: *Innovations and Challenges. ncoa* 10: 238. DOI: 10.4172/2469-9780.2025.10.3.238